Background: The effects of the programed cell death 1 (PDCD1) gene polymorphisms on cancer risk have been investigated in some studies; however, the results were conflicting and ambiguous. Therefore, we aimed to do a meta-analysis to investigate the association of PDCD1 polymorphisms with cancer risk from all eligible case-control studies.
Introduction
Programed cell death-1 (PDCD1) is an immunoreceptor belonging to the CD28/CTLA-4 family. [1] It is a 55-kd types I transmembrane glycoprotein and a member of the immunoglobulin superfamily B7. [2] [3] [4] It is expressed on activated B cells, T cells, and monocytes, and its ligand (PD-L) on immune and nonimmune cells including tumor cells. [5] PD-1 was first identified by Ishida in 1992, [6] its function of negatively regulation in immune response was later found by the generation of PDCD1 −/− mice. [7] PD-1 is involved in almost every aspect of immune responses including autoimmunity, tumor immunity, infectious immunity, transplantation immunity, allergy, and immunological privilege. [1] The human PDCD1 gene is located on 2q37.3. In the PDCD1 gene, several polymorphisms have been identified, such as PDCD-1.1 (rs36084323), PDCD-1.3 (rs11568821), PDCD-1.5 (rs2227981), PDCD-1.9 (rs2227982), and so on. [8] [9] [10] The association between polymorphisms in PDCD1 gene and cancer risk has been studied in many studies. However, these associations were still inconclusive. [8] [9] [10] [11] [12] [13] Although a meta-analysis reported the association between PDCD-1.5 (rs2227981) polymorphism and the risk of cancer [14] ; however, they only reported 1 polymorphism and did not report the exact search date. The association between other polymorphisms with cancer risk should also be assessed. Thus, we conducted a comprehensive meta-analysis to investigate the association of PDCD1 gene polymorphisms and cancer risk.
(table S1, http://links.lww.com/MD/B255). [15] The present study is a meta-analysis, and ethical approval was not necessary.
Literature search
A literature search of the PubMed, EMbase, Chinese National Knowledge Infrastructure, and WanFang databases was carried out to collect the case-control studies that investigated the association between polymorphisms of PDCD1 gene and the risk of cancer. The date was extended to December 10, 2015. The search words were as follows: polymorphism, variant, cancer, carcinoma, PDCD1, and programed death-1.
Inclusion and exclusion criteria
We selected eligible studies according to the following criteria: case-control studies, investigating the association between the PDCD1 polymorphisms and cancer risk, detailed genotype data for estimating of odds ratio (OR) and 95% confidence interval (CI), and articles written in English or Chinese. Exclusion criteria were the following: insufficient information on the distribution of PDCD1 genotypes, case-only studies, and duplicated publications. If multiple studies had overlapping or duplicate data, only those with complete data were included.
Data extraction
Data extraction was performed independently by 2 of the authors (JZ and TZ) using a standard protocol according to the inclusion criteria. The following data were extracted: the name of the first author, year of publication, country of participants, ethnicity, genotyping methods, and genotype distribution of cases and controls. Disputes were settled by discussion.
Statistical analysis
Any polymorphism studied in at least 3 case-control studies was included for data analysis. Crude ORs with 95% CIs were calculated to evaluate the strength of the association between PDCD1 polymorphisms and cancer risk. [16, 17] All genetic models (additive, dominant, recessive, and codominant) were used to assess the association. [17, 18] Take the PDCD-1.9 (rs2227982) polymorphism as an example, the genetic models were as follows: additive model (C vs T), dominant model (CC + CT vs TT), recessive model (CC vs TT + CT), and codominant model (CC vs TT, CT vs TT). A statistical test for heterogeneity was performed based on the Q statistic. [19] If P < 0.10 for Q test suggested significant heterogeneity, then the random effects model was conducted to calculate the pooled OR; otherwise, the fixed effects model was selected. [18, 20] Sensitivity analysis was performed by omitting each study in turn to assess the quality and consistency of the results. Begg funnel plot and the Egger test were used to evaluate possible publication bias of literatures. [21] All statistical tests were performed by using Revman 5.3 software (The Cochrane Collaboration, UK) and STATA 12.0 software (Stata Corporation, College Station, TX). P values <0.05 were considered statistically significant. Table 1 The characteristics of the included studies.
Reference
Year Country Ethnicity Cancer
Genotyping method Polymorphisms
Bayram et al [22] 2012 Turkey European HCC PCR-RFLP rs11568821 Ge et al [24] 2015
China Asian Colorectal PCR-RFLP rs7421861, rs2227982, and rs10204525 Haghshenas et al [24] 2011
Iran Asian Breast PCR-RFLP rs2227981 and rs11568821 Hua et al [2] 2011 China Asian Breast PCR-RFLP rs7421861, rs 2227981, and rs2227982 Ivansson et al [3] 2010 Sweden European Cervical Taqman rs2227981 Li et al [4] 2013
China Asian HCC PCR-RFLP rs10204525 Ma et al [5] 2015
China Asian Lung PCR-RFLP rs11568821, rs2227981, and rs2227982 Mojtahedi et al [8] 2012
Iran Asian Colorectal PCR-RFLP rs2227981 Qiu et al [9] 2014 China Asian Esophageal PCR-LDR rs7421861, rs 2227982, and rs10204525 Savabkar et al [10] 2013
Iran Asian Gastric PCR-RFLP rs2227981 Tang et al [11] 2015
China Asian Gastric PCR-LDR rs2227982, rs10204525, and rs7421861 Yin et al [12] 2014
China Asian Lung PCR rs2227981 Yousefi et al [13] 2013
Iran Asian Colorectal PCR-RFLP rs11568821 HCC = hepatocellular carcinoma. Table 2 The genotypes and alleles distributions of included polymorphisms. [12] 198 106  20  181  105  44  146  146  467  193  rs2227982  TT  TC  CC  TT  TC  CC  T  C T C Ge et al [24] [11] 169
Polymorphism
123 21 309 219 53 165 165 837 325 Zhang et al. Medicine (2016) 95:40 www.md-journal.com
Results

Eligible studies
We initially identified 1066 potentially relevant studies after searching the databases. After excluding the duplicated records, 578 studies were left for screening. After reading the title and the abstracts of these studies, 555 studies were excluded for not reporting the association between the PDCD-1 polymorphisms and cancer risks reviews. Thus, 23 studies were left for full-text assessment and data extraction. Among these studies, 2 studies were excluded for not reporting useful data for meta-analysis, 3 were excluded for not being case-control studies, and 5 were excluded for not reporting polymorphism in more than 3 case-control studies. Thus, 13 studies that met the predescribed inclusion criteria were included in the meta-analysis of the association between PDCD1 polymorphisms and cancer risk (Fig. 1) . [2] [3] [4] [5] [8] [9] [10] [11] [12] [13] [22] [23] [24] Characteristics of all eligible case-control studies are summarized in Table 1 . There were 7 case-control studies on PDCD-1.5 (rs2227981) polymorphism, [2, 3, 5, 8, 10, 12, 24] 5 on PDCD-1.9 (rs2227982) polymorphism, [2, 5, 9, 11, 23] 4 on rs7421861 polymorphism, [2, 9, 11, 23] 4 on PDCD-1.3 (rs11568821) polymorphism, [5, 13, 22, 24] and 4 on PDCD-1.6 (rs10204525) polymorphism, [4, 9, 11, 23] respectively. Of the 13 included studies, 7 types of cancers including gastric, breast, esophageal, liver (hepatocellular carcinoma), colorectal, cervical, and lung cancer were involved. The genotype distributions in the studies considered in the present meta-analysis are shown in Table 2 . 
Meta-analysis results
The summary results for the association between PDCD-1 polymorphisms and the risk of cancer are shown in Table 3 . For the PDCD-1.5 (rs2227981) polymorphism, we found a significant association between the polymorphism and overall cancer risk in the recessive genetic model (OR = 0.75, 95% CI: 0.64-0.86, P < 0.0001) (Fig. 2) . For the PDCD-1.9 (rs2227982) polymorphism, there was no statistical evidence of an association between the polymorphism and overall cancer risk in the dominant genetic model (OR = 1.03, 95% CI: 0.90-1.18, P = 0.66) (Fig. 3) . For the rs7421861 polymorphism, there was no statistical evidence of an association between the polymorphism and overall cancer risk in the dominant genetic model (OR = 1.10, 95% CI: 0.96-1.25, P = 0.16) (Fig. 4) . For the PDCD-1.3 (rs11568821) polymorphism, there was statistical evidence of an association between the polymorphism and overall cancer risk in TC versus TT genetic model (OR = 0.79, 95% CI: 0.65-0.96, P = 0.02) (Fig. 5) . For the PDCD-1.6 (rs10204525) polymorphism, there was no statistical evidence of an association between the polymorphism and overall cancer risk (OR = 0.93, 95% CI: 0.82-1.05, P = 0.24) (Fig. 6 ). 
Publication bias
Discussion
Accumulative evidence suggests that PDCD1 is a negative regulator of the immune response. [5, 11, 23] Genetic variants in PDCD1 gene have been associated with the pathogenesis of cancers. Several important variants in the gene have been identified, such as the PDCD-1.5 (rs2227981) polymorphism, PDCD-1.9 (rs2227982), and so on. [5, 9] Up to now, the associations between polymorphisms in the PDCD1 gene and the risk of cancer were still inconclusive; thus, we performed the current meta-analysis. To the best of our knowledge, this is the first comprehensive meta-analysis to assess the association of PDCD1 gene polymorphisms with the risk of cancer.
The current meta-analysis, which included a total of 24 case-control studies from 13 articles, investigated the associations of 5 widely studied polymorphisms in PDCD1 gene and cancer risk. The results indicated that the variant TT genotype of the rs2227981 polymorphism and TC genotype of the rs11568821 polymorphism were associated with significant decreased risk of cancer, whereas the other 3 polymorphisms (rs2227982, rs7421861, and rs10204525) did not appear to have a significant association with cancer risk. Previous studies reported that the PDCD-1.5 (rs2227981) polymorphism was an asynonymous mutation (C to T, Ala to Ala) [2, 24] ; it may influence the expression and function of PDCD1 through linkage disequilibrium with other nucleotide polymorphisms in PDCD1 gene or other nearby genes. [2, 24] Accordingly, the polymorphism may influence the susceptibility to cancer through these mechanisms.
In this meta-analysis, we also found that the PDCD-1.3 (rs11568821) polymorphism was significantly associated with decreased risk of cancer, and the genotype TC might be a risk factor. A possible reason might be that this polymorphism (T to C) was a polymorphism in the fourth intron of PDCD1, [24] the substitution of T for C in the enhancer within the intron might disrupt the binding site of RUNX1, alter the regulation of gene expression, and influence the PD-1 pathway. [24] PDCD-1.3 (rs11568821) polymorphism may impair the inhibitory effect of PD-1 and thus may lead to positive regulation of cytotoxic lymphocyte activity in T allele carriers. [5, 24] Thus, variant TC genotype might contribute to decrease risk of cancer. However, the exact mechanisms are still needed to be analyzed in future studies. However, 11 Asian studies were included in our metaanalysis, and the majority were studies performed in China. Race might play an important role in deriving the conclusions of the current meta-analysis. Some studies have a bigger sample size compared with others within 1 analysis, which might also generate bias. This suggests that the results should be explained with caution.
The problem of heterogeneity and publication bias, which may influence the results of meta-analyses, should also be explained. Significant heterogeneity existed in the analysis among 3 polymorphisms. The heterogeneity might result from cancer types, ethnicity, and the source of controls. However, due to the limited number of studies included, we did not perform analysis of these factors based on subgroups. Publication bias is another important issue in meta-analyses. In the present study, publication bias was analyzed by using Begg funnel plots and the Egger test. We did not detect a significant publication bias for all polymorphisms, suggesting the reliability of our results.
This meta-analysis has pooled the available data from the eligible studies, which has significantly increased the statistical power. However, there are still some weaknesses. First, cancer is a multifactorial disease from complex interactions between environmental exposure and genetic factors. In this metaanalysis, we had insufficient data to conduct an evaluation of such interactions for the role of PDCD1 polymorphisms and factors in cancer development. Second, numerous present studies are limited for some polymorphisms only. Thus, investigations involving large number of different ethnicities are necessary for a more reliable assessment on their associations. Third, the heterogeneity between studies exists in some polymorphisms, and that may affect the stability of the results.
In conclusion, our meta-analysis suggests that PDCD-1.5 (rs2227981) and PDCD-1.3 (rs11568821) polymorphisms are associated with susceptibility to cancer, while rs2227982, rs7421861, and rs10204525 polymorphism may not be associated with cancer risk. These results should be interpreted cautiously. In order to better understand the potential roles of PDCD1 polymorphisms in cancer, further studies with larger sample sizes, combining genetic and other environmental risk factors, are needed. 
